News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pharma Two B Ltd. Commences Phase 2b Study Of Fixed Dose Combination Therapy “P2B001” For Parkinson’s Disease


3/18/2014 9:25:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REHOVOT, Israel--(BUSINESS WIRE)--Pharma Two B announced today that it is now enrolling patients for a Phase IIb study of its combination product, P2B001, for the treatment of the early stages of Parkinson’s disease (PD). Pharma Two B is following the FDA’s 505(b)(2) registration pathway for P2B001.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES